Workshops

Monday 27 May 11:00-12:15

Lipoproteins, lipids and atherosclerosis

Lipolysis of triglyceride-rich lipoproteins, vascular inflammation, and atherosclerosis

Jan Borén, Gothenburg, Sweden

Modified lipids and lipoproteins

JL Witztum, San Diego, USA


Wednesday 29 May 11:00-12:15

Omics in predicting CV risk

Shot-gun proteomics to assess vulnerable plaques and future CV risk

Evgeni Levin, North Holland Province, The Netherlands

Is metabolomics adding something to CV risk assesment?

Katey Rynar, Ottawa, Canada


Tuesday 28 May 15:45-17:00

Lipoproteins and Immunity

Immune checkpoints in atherosclerosis / T-cells

Esther Lutgens, Amsterdam, The Netherlands


Tuesday 28 May 11:00-12:15

Cellular crosstalk and plaque stability

Extracellular vesicles as new pharmacological targets to treat atherosclerosis

Dominique de Kleijn, Utrecht, The Netherlands


Wednesday 29 May 11:00-12:15

Celluar metabolism in atherosclerosis and diabetes

Stimulating energy metabolism to combat type 2 diabetes; insight from human translational interventions

Heribert Schunkert, Munich, Germany


Monday 27 May 11:00-12:15

Fatty liver and CVD

Nonalcoholic fatty liver disease and vascular complications

Jay Horton, Dallas, USA


Monday 27 May 15:45-17:00

Vascular biology in atherosclerosis

Sortilin in vascular calcification

Elena Aikawa, Boston, USA

Circular non-coding RNA ANRIL modulates ribosomal RNA maturation and atherosclerosis in humans

Lesca Holdt, London, UK


Wednesday 29 May 11:00-12:15

Metabolic dysfunction and CVD

Gut microbiome and cardioascular disease: from promise to delivery

Max Nieuwdorp, Amsterdam, The Netherlands

Brown fat to combat cardiovascular disease

Patrick Rensen, Leiden, The Netherlands


Tuesday 28 May 11:00-12:15

Hematopoietic cells and CVD

Interaction between hemopoeitic cells and endothelium in vasculature

Luisa Iruela-Arispe, Los Angeles, USA

Clonal hematopoiesis in cardiovascular disease states

Siddhartha Jaiswal, Palo Alto, USA


Monday 27 May 15:45-17:00

Cardiovascular risk assessment from epidemiology to genetics

Phenotype, genotype or epigenetics?

Ruth Frikke-Schmidt, Copenhagen, Denmark

What have we learned about CVD risk from genome-wide association studies?

Heribert Schunkert, Munich, Germany


Tuesday 28 May 11:00-12:15

Novel targets for controlling dyslipidaemias

New targets for controlling dyslipidaemias

John Kastelein, Amsterdam, The Netherlands


Tuesday 28 May 15:45-17:00

Vascular ageing

The aging cardiovascular system

Giovanni G. Camici, Zurich, Switzerland

Molecular markers of vascular aging

Michael Sieweke, Marsberg, Germany